The Medicines Company's Cangrelor Bridge Trial Published in the Journal of the American Medical Association
(firmenpresse) - PARSIPPANY, NJ -- (Marketwire) -- 01/17/12 -- The Medicines Company (NASDAQ: MDCO) today announced publication in the Journal of the American Medical Association (JAMA) of clinical trial results from testing of cangrelor, an investigational intravenous antiplatelet.
The article, "Bridging Antiplatelet Therapy With Cangrelor in Patients Undergoing Cardiac Surgery," is available in the January 18 JAMA issue under Original Contributions.
Cangrelor is an investigational intravenous small molecule antiplatelet agent not approved for commercial use in any market. BRIDGE is a prospective, randomized, double-blind, placebo-controlled multicenter trial which evaluated cangrelor or placebo in 210 patients with an acute coronary syndrome (ACS) or treated with a coronary stent and receiving a thienopryidine awaiting coronary artery bypass graft (CABG) surgery. The primary efficacy endpoint was platelet reactivity. The main safety endpoint was excessive CABG-surgery related bleeding. In October 2010, The Medicines Company initiated a Phase 3 clinical trial called PHOENIX to evaluate cangrelor in patients undergoing percutaneous coronary intervention (PCI).
The Medicines Company (NASDAQ: MDCO) provides medical solutions to improve health outcomes for patients in acute and intensive care hospitals worldwide. These solutions comprise medicines and knowledge that directly impact the survival and well-being of critically ill patients.
Contact:
Michael Mitchell
The Medicines Company
+973-290-6000
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 17.01.2012 - 15:34 Uhr
Sprache: Deutsch
News-ID 1073836
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
PARSIPPANY, NJ
Phone:
Kategorie:
Biotech
Anmerkungen:
Diese Pressemitteilung wurde bisher 215 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"The Medicines Company's Cangrelor Bridge Trial Published in the Journal of the American Medical Association
"
steht unter der journalistisch-redaktionellen Verantwortung von
The Medicines Company (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
